VEGFR2
- 产品详情
- 实验流程
Primary Accession | P35968-1 |
---|---|
Species | Human |
Sequence | Ala20-Glu764 |
Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
Endotoxin Level | Less than 1 EU per µg by the LAL method. |
Biological Activity | Immobilized VEGFR2, Avi & His, Human (Cat.No.: Z03811) at 0.5 µg/ml can bind AntiVEGFR2 Antibody. |
Expression System | HEK293 |
Theoretical Molecular Weight | 86.2 kDa |
Formulation | Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. |
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability | Upon receiving, the lyophilized product remains stable up to 6 months at -20 °C or below as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Target Background | The kinase insert domain receptor (KDR), also known as vascular endothelial growth factor receptor 2 (VEGFR-2), is a type IV receptor tyrosine kinase that plays a crucial role in various biological processes, including embryonic vasculature development, angiogenesis regulation, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. It acts as a cell-surface receptor for VEGFA, VEGFB, and PGF. The human gene encoding KDR is also known as CD309 and Flk1 (Fetal Liver Kinase 1). VEGFR2 is a key regulator of angiogenesis. |
---|
Research Areas
For Research Use Only. Not For Use In Diagnostic Procedures.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.